BPC-157 20mg is a high-purity synthetic pentadecapeptide investigated in preclinical models for its role in cellular migration, angiogenesis, and tissue repair. This guide provides laboratory researchers with analytical specifications, lot-specific COA verification standards, and reconstitution parameters for in vitro and animal models.
BPC-157 20mg is a high-purity synthetic pentadecapeptide investigated in preclinical models for its role in cellular migration, angiogenesis, and tissue repair. This guide provides laboratory researchers with analytical specifications, lot-specific COA verification standards, and reconstitution parameters for in vitro and animal models.
BPC-157 20mg (Body Protection Compound 157, amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a synthetic 15-amino-acid peptide derived from a human gastric juice protein fragment. In preclinical research settings, the 20mg bulk vial format is utilized for high-throughput in vitro assays and extended animal model protocols evaluating accelerated repair across tendon, ligament, skeletal muscle, and gastrointestinal epithelial tissues.
When sourcing BPC-157 20mg, research integrity depends on rigorous analytical verification. Every lot produced for PX1 Research undergoes independent ISO 17025 third-party testing, providing a comprehensive BPC-157 COA that documents purity levels exceeding 99% via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), sequence confirmation via Electrospray Ionization Mass Spectrometry (ESI-MS), and strict bacterial endotoxin screening.
Evaluating research peptide suppliers requires transparent analytical data to ensure experimental reproducibility and minimize laboratory contamination. Lower-grade synthetic peptides often introduce variable counter-ion content, synthesis by-products, and unquantified endotoxins that compromise cellular assays.
The following parameters define the structural quality and analytical baseline for PX1 Research reference-grade compounds:
• Chemical Purity: ≥99.0% verified by RP-HPLC peak area integration. • Mass Verification: Exact molecular weight of 1419.53 Da confirmed via ESI-MS. • Endotoxin Threshold: <0.5 EU/mg assessed via Limulus Amebocyte Lysate (LAL) assay. • Physical Form: Sterile lyophilized cake produced in GMP-compliant facilities. • Documentation: Lot-specific third-party COA attached to every shipment. • Fulfillment: Same-day shipping on orders placed Monday–Friday from California and Arizona logistics hubs.
Researchers seeking high-volume material for institutional studies can access scaled packaging through our dedicated wholesale lab accounts program.
BPC-157 is a stable pentadecapeptide with a molecular formula of C62H98N16O22 and a precise molecular mass of 1419.53 g/mol. Unlike many naturally occurring signaling peptides, BPC-157 exhibits unusual structural stability in biological fluids and acidic environments due to its specific sequence architecture.
In primary laboratory literature, this sequence is categorized under gastroprotective and regenerative signaling molecules. The compound lacks secondary or tertiary folding constraints, functioning as a linear peptide that interacts with focal adhesion complexes and cell-surface growth factor receptors. Researchers investigating structural variants or alternative unit sizes can review our full all research peptides catalog for complementary formulations.
The primary mechanism of action characterized in preclinical literature centers on the upregulation of Vascular Endothelial Growth Factor (VEGF) expression and VEGFR2 activation. In vitro capillary tube formation assays demonstrate that exposure to BPC-157 accelerates endothelial cell proliferation and directional migration.
Preclinical studies suggest that BPC-157 stimulates the activation of the FAK-Paxillin signaling pathway, which controls cellular adhesion dynamics and cytoskeletal reorganization. This pathway is critical during wound healing cascades, where fibroblasts and endothelial cells must rapidly migrate into lesion sites. Detailed analysis of these cascades is documented within our angiogenesis peptides reference index.
Rodent models of transected or crushed Achilles tendons, medial collateral ligaments (MCL), and quadriceps muscles have served as the primary benchmark for assessing the regenerative capacity of BPC-157. In these models, administration of the peptide correlates with accelerated biomechanical recovery, including increased peak load to failure and enhanced tensile strength.
Histological evaluations of treated tendinous tissues demonstrate organized collagen bundle deposition (predominantly Type I collagen restoration over disorganized Type III scar tissue) and increased fibroblast density. Researchers exploring musculoskeletal regeneration models can find comparative dataset overviews in our dedicated tissue repair research hub.
Originally isolated as a fragment of gastric cytoprotective protein, BPC-157 has been extensively evaluated in animal models of inflammatory bowel disease (IBD), gastric ulceration, and NSAID-induced enteropathy. In vitro studies using intestinal epithelial monolayers (such as Caco-2 cell lines) show that BPC-157 enhances mucosal integrity by modulating tight junction proteins including Claudin-1 and Occludin.
In vivo rodent assays indicate that BPC-157 counteracts erosive lesions caused by corrosive agents or systemic organ damage models. It appears to modulate nitric oxide (NO) synthase activity, balancing endothelial NO (eNO) production for local blood flow maintenance while attenuating inducible NO (iNO) associated with excessive tissue inflammation. For additional background on mucosal protection pathways, consult our pentadecapeptide BPC-157 overview.
When designing tissue regeneration protocols, researchers frequently compare BPC-157 against other leading peptides in the repair category. While BPC-157 acts predominantly through VEGFR2 activation, FAK-Paxillin migration pathways, and localized cytoprotection, alternative peptides target complementary biochemical cascades.
For example, TB-500 (Synthetic Thymosin Beta-4 fragment) functions primarily via actin monomer sequestration, promoting cell motility and systemic tissue remodeling. Meanwhile, GHK-Cu operates by modulating copper-dependent gene transcription, collagen cross-linking, and antioxidant enzyme upregulation. Laboratories often compare these mechanisms or evaluate synergistic co-administration models, utilizing our standard BPC-157 5mg format alongside companion peptides for smaller exploratory trials.
A lot-specific Certificate of Analysis (COA) provides essential verification of compound identity, purity, and safety before initiating laboratory trials. When analyzing a BPC-157 COA from PX1 Research, investigators should focus on three critical analytical outputs:
1. RP-HPLC Chromatogram: Shows the retention time and peak area percentage. A main peak representing ≥99.0% of total area ensures minimal truncated peptide impurities. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms the observed mass charge ratio (m/z) matches the theoretical molecular weight of 1419.53 Da. 3. Endotoxin Quantitation (LAL Assay): Measures residual lipopolysaccharides, ensuring levels remain well below the <0.5 EU/mg threshold required for sensitive cell culture assays.
Every batch manufactured for PX1 undergoes testing in an independent, ISO 17025 accredited laboratory within the United States, guaranteeing verifiable documentation for every purchase.
BPC-157 20mg is supplied as a lyophilized (freeze-dried) powder under vacuum seal. To maintain structural integrity during reconstitution, laboratory personnel should adhere to standard aseptic techniques within a laminar flow hood.
Bacteriostatic Water (0.9% benzyl alcohol preserved) or Sterile Normal Saline (0.9% NaCl) are the recommended diluents for reconstitution. When adding liquid to the vial, direct the stream gently against the glass wall rather than directly onto the lyophilized cake to prevent shear stress. Allow the cake to dissolve naturally or gently swirl the vial; never agitate or vortex vigorously, as mechanical turbulence can cause aggregation of peptide chains.
Lyophilized BPC-157 20mg should be stored at -20°C for long-term storage (up to 24 months) or 2°C to 8°C for short-term usage (up to 90 days), protected from direct light exposure. Avoid repeated freeze-thaw cycles, which accelerate physical degradation.
Once reconstituted with bacteriostatic water, liquid solutions remain chemically stable at 2°C to 8°C for up to 30 days. For long-term liquid storage, reconstitute in sterile buffer, aliquot into single-use polypropylene tubes, and flash-freeze at -80°C. Further storage specifications and technical whitepapers are accessible through the central PX1 research library.
What is the primary specification of BPC-157 20mg?
BPC-157 20mg is a synthetic 15-amino-acid research peptide (MW 1419.53 Da) supplied as a lyophilized powder with ≥99% purity verified by RP-HPLC, intended strictly for laboratory in vitro and preclinical research.
How do I access the BPC-157 COA for my specific lot?
Every lot of BPC-157 20mg from PX1 Research includes a lot-specific Certificate of Analysis. The COA can be downloaded directly from our site or accessed via the PX1 research portal using your batch control number.
What purity levels are confirmed on the BPC-157 COA?
PX1 Research guarantees a chemical purity of ≥99.0% as integrated by RP-HPLC peak area analysis, with mass sequence identity verified via ESI mass spectrometry.
What are the endotoxin limits for BPC-157 20mg?
All batches are tested via Limulus Amebocyte Lysate (LAL) assays to ensure endotoxin content remains strictly below <0.5 EU/mg, preventing cell culture contamination or confounding inflammatory responses.
What solvent should be used for reconstituting BPC-157 20mg in laboratory assays?
Bacteriostatic water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4) are standard diluents depending on whether long-term liquid storage or biological cell culture compatibility is required.
How should reconstituted BPC-157 20mg solutions be stored?
Reconstituted liquid solutions should be stored at 2°C to 8°C and used within 30 days when prepared with bacteriostatic water. Single-use aliquots can be frozen at -80°C for extended experimental protocols.
Where is PX1 BPC-157 manufactured and shipped from?
PX1 Research peptides are manufactured in US-based GMP-compliant facilities and ship directly from our distribution hubs in California and Arizona with same-day fulfillment on business days.
How does BPC-157 20mg compare to the 5mg format?
Both formats contain identical high-purity (>99%) synthetic BPC-157. The 20mg vial offers higher total quantity for extended animal studies or high-throughput screening assays requiring larger working volumes.
Which preclinical pathways are most commonly studied with BPC-157?
BPC-157 is primarily studied in relation to VEGFR2 pathway activation, FAK-Paxillin migration cascades, nitric oxide synthase modulation, and tight-junction protein upregulation in mucosal barrier models.
Can BPC-157 20mg be ordered for institutional bulk research?
Yes, high-volume laboratories and academic institutions can request bulk quantities and volume pricing through PX1 wholesale lab accounts.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.